Y
Yongkun Sun
Researcher at Peking Union Medical College
Publications - 39
Citations - 959
Yongkun Sun is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Cancer & Survival rate. The author has an hindex of 10, co-authored 39 publications receiving 614 citations.
Papers
More filters
Journal ArticleDOI
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Yongkun Sun,Wei Niu,Feng Du,Chun-Xia Du,Shuting Li,Jinwan Wang,Li Li,Fengqing Wang,Yu Hao,Chuan Li,Yihebali Chi +10 more
TL;DR: At the dose of 12 mg once daily at the 2/1 schedule, anlotinib displayed manageable toxicity, long circulation, and broad-spectrum antitumor potential, justifying the conduct of further studies.
Journal ArticleDOI
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Yihebali Chi,Zhiwei Fang,Xiaonan Hong,Yang Yao,Ping Sun,Guowen Wang,Feng Du,Yongkun Sun,Q. Wu,Guofan Qu,Shusen Wang,Jianmin Song,Jian-Chun Yu,Yongkui Lu,Xia Zhu,Xiaohui Niu,Zhiyong He,Jinwan Wang,Hao Yu,Jianqiang Cai +19 more
TL;DR: Anlotinib showed antitumor activity in several STS entities and the toxicity was manageable, and the most common clinically significant grade 3 or higher adverse events were hypertension, triglyceride elevation, and pneumothorax.
Journal ArticleDOI
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Yongkun Sun,Feng Du,Ming Gao,Qinghai Ji,Zhendong Li,Yuan Zhang,Zhuming Guo,Jun Wang,Xiangjin Chen,Jinwan Wang,Yihebali Chi,Pingzhang Tang +11 more
TL;DR: Anlotinib demonstrated a durable antitumor activity with a manageable adverse event profile in locally advanced or metastatic MTC.
Journal ArticleDOI
Effects of retrograde autologous priming on blood transfusion and clinical outcomes in adults: a meta-analysis
TL;DR: Compared to conventional priming, RAP could reduce transfusion in adults significantly, but had no effect on clinical outcomes, comparing to conventionalPriming.
Journal ArticleDOI
Superiority of Letrozole to Tamoxifen in the First-Line Treatment of Advanced Breast Cancer: Evidence from Metastatic Subgroups and a Test of Functional Ability
H. Mouridsen,Yongkun Sun,M. Gershanovich,R. Perez-Carrion,D. Becquart,H. A. Chaudri-Ross,R. Lang +6 more
TL;DR: Data demonstrate the consistent superiority of letrozole over tamoxifen and support the use of let rozole as a new standard of endocrine therapy in postmenopausual women with advanced breast cancer.